-
03:53:58 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

VTGN Stock News

06/22/22 8:30 AM
Nasdaq : VTGN
clinical trial
VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder
VistaGen Therapeutics, Inc., a late clinical-stage central nervous system- focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, today announced that the last patient has completed the study protocol in its PALISADE-1 Phase 3 clinical trial of PH94B for the...
RHEA-AI
very positive
06/17/22 8:30 AM
Nasdaq : VTGN
conferencesearnings
VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022
VistaGen Therapeutics, Inc. a late clinical-stage, central nervous system- focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, today announced it will host a conference call and webcast on Thursday, June 23, 2022, at 2:00 p.m. Pacific Time to report its...
RHEA-AI
neutral
06/02/22 8:30 AM
Nasdaq : VTGN
conferencesclinical trial
VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting
VistaGen Therapeutics, Inc., a late clinical-stage, central nervous system- focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced that the clinical trial abstract for its exploratory Phase 2 A clinical study in adjustment disorder with...
RHEA-AI
neutral
05/05/22 8:30 AM
Nasdaq : VTGN
VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder
VistaGen Therapeutics, Inc., a late clinical-stage, central nervous system focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, announced today a key regulatory update on its PALISADE Phase 3 Program for PH94B for the acute treatment of anxiety in adults...
RHEA-AI
negative
04/21/22 8:00 AM
Nasdaq : VTGN
conferencesclinical trial
VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses
VistaGen Therapeutics, Inc. a late clinical-stage, central nervous system focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, announced that researchers will present preclinical data supporting the differentiated mechanism of action for VistaGen’ s...
RHEA-AI
neutral